AVLN (Avalyn Pharma) EV-to-EBIT: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Avalyn Pharma's Enterprise Value is $1,156.77 Mil. Avalyn Pharma does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Avalyn Pharma's EV-to-EBIT at this moment.

The historical rank and industry rank for Avalyn Pharma's EV-to-EBIT or its related term are showing as below:

AVLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.08   Med: 0   Max: 0
Current: -12.67
AVLN's EV-to-EBIT is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 12.63 vs AVLN: -12.67

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Avalyn Pharma's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil. Avalyn Pharma does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Avalyn Pharma's Earnings Yield (Joel Greenblatt) % at this moment.

Avalyn Pharma  (NAS:AVLN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Avalyn Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/0
= %

Avalyn Pharma EV-to-EBIT Related Terms

Avalyn Pharma EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma EV-to-EBIT Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 0.00

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

AVLN vs TRAX, IMTX, ARDX: EV-to-EBIT Comparison

For the Biotechnology subindustry, Avalyn Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalyn Pharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's EV-to-EBIT falls into.


AVLN
11GF Score
Avalyn Pharma Inc AVLN
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma EV-to-EBIT Calculation

Avalyn Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1156.774/
=

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price